TUCSON, Ariz., March 26 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. today announced that the Company has rescheduled a live webcast and conference call, which will now take place on Monday, March 31, 2008, at 5:00 p.m. ET to discuss corporate updates and financial results for the fourth quarter and full year 2007.
The live webcast can be accessed through ImaRx's corporate website at http://www.imarx.com/ and will be archived on the website for 14 days following the event.
Interested parties may access the conference call by dialing (877) 407- 4018 in the U.S. and Canada or (201) 689-8471 internationally. A telephonic replay will be available through April 8, 2008 by dialing (877) 660-6853 in the U.S. and Canada or (201) 612-7415 internationally (Account Number 3055 and Conference ID 279436).
About ImaRx Therapeutics
ImaRx Therapeutics is a biopharmaceutical company commercializing and developing therapies for vascular disorders. The Company's commercialization efforts are currently focused on its FDA approved product, urokinase, for the treatment of acute massive pulmonary embolism. The Company's research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology.
Contacts:
The Ruth Group (Investors/Media)
Sara Ephraim/Jason Rando
646-536-7002 or 7025
